# Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

> **NCT05775406** · PHASE1 · COMPLETED · sponsor: **Kymera Therapeutics, Inc.** · enrollment: 52 (actual)

## Conditions studied

- Myeloid Malignancies
- Acute Lymphocytic Leukemia
- Lymphomas
- Advanced Solid Tumors

## Interventions

- **DRUG:** KT-253

## Key facts

- **NCT ID:** NCT05775406
- **Lead sponsor:** Kymera Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-15
- **Primary completion:** 2024-12-18
- **Final completion:** 2024-12-18
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05775406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05775406, "Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05775406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*